YRBAF yields 4434.59% · PFE yields 6.13%● Live data
📍 YRBAF pulled ahead of the other in Year 1
Combined, YRBAF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YRBAF + PFE for your $10,000?
Yorbeau Resources Inc. engages in the acquisition, exploration, and development of mineral properties in Canada. It explores for gold, silver, copper, zinc, and other base metals. The company holds 100% interests in the Rouyn property that consists of 1 mining concession and 94 claims having a total area of 2,684.88 hectares (ha) located in the south of Rouyn-Noranda, Québec; the Scott Lake property comprises three non-contiguous claim blocks consisting of 123 complete or partial claim cells covering an area of approximately 6,089 ha located in the townships of Lévy, Scott, and Obalski in northwestern Québec; and the Estrades-Caribou property, which consists of three contiguous claim blocks totaling 118 claims located in the Estrées Township in Québec. It also owns 100% interests in the Beschefer property that comprises 128 claims located in the Beschefer Township of northwestern Quebec; the Selbaie West property consists of 105 claims located in the Carheil and Brouillan townships in Québec; the Landrienne property, which consists of 59 claims located in the Landrienne Township in Québec; the Lemoine property comprising 102 claims located in the Lemoine, Rinfret, and Dollier townships in Québec; and the Castagnier property. In addition, the company holds interests in the Joutel-Explo Zinc project consisting of 118 claims and 1 mining concession; the Gemini-Turgeon projects comprises 189 claims; and the Allard property, which includes 43 claims located in the Abitibi region of Québec. Yorbeau Resources Inc. was incorporated in 1984 and is headquartered in Montreal, Canada.
Full YRBAF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.